MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $629.92 million. The enterprise value is $486.33 million.
| Market Cap | 629.92M |
| Enterprise Value | 486.33M |
Important Dates
The next estimated earnings date is Wednesday, April 29, 2026, after market close.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 148.57 million shares outstanding. The number of shares has increased by 0.45% in one year.
| Current Share Class | 148.57M |
| Shares Outstanding | 148.57M |
| Shares Change (YoY) | +0.45% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 2.07% |
| Owned by Institutions (%) | 53.24% |
| Float | 117.30M |
Valuation Ratios
The trailing PE ratio is 13.25 and the forward PE ratio is 49.88.
| PE Ratio | 13.25 |
| Forward PE | 49.88 |
| PS Ratio | 1.50 |
| Forward PS | 1.63 |
| PB Ratio | 2.45 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | 8.63 |
| P/OCF Ratio | 8.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.17, with an EV/FCF ratio of 6.66.
| EV / Earnings | 10.01 |
| EV / Sales | 1.16 |
| EV / EBITDA | 6.17 |
| EV / EBIT | 7.61 |
| EV / FCF | 6.66 |
Financial Position
The company has a current ratio of 4.32, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.32 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | 0.31 |
| Interest Coverage | 35.83 |
Financial Efficiency
Return on equity (ROE) is 21.61% and return on invested capital (ROIC) is 41.08%.
| Return on Equity (ROE) | 21.61% |
| Return on Assets (ROA) | 13.17% |
| Return on Invested Capital (ROIC) | 41.08% |
| Return on Capital Employed (ROCE) | 22.95% |
| Weighted Average Cost of Capital (WACC) | 12.79% |
| Revenue Per Employee | $518,106 |
| Profits Per Employee | $60,121 |
| Employee Count | 808 |
| Asset Turnover | 1.38 |
| Inventory Turnover | 2.97 |
Taxes
In the past 12 months, MiMedx Group has paid $17.68 million in taxes.
| Income Tax | 17.68M |
| Effective Tax Rate | 26.69% |
Stock Price Statistics
The stock price has decreased by -47.26% in the last 52 weeks. The beta is 1.60, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -47.26% |
| 50-Day Moving Average | 5.16 |
| 200-Day Moving Average | 6.44 |
| Relative Strength Index (RSI) | 22.55 |
| Average Volume (20 Days) | 938,459 |
Short Selling Information
The latest short interest is 6.71 million, so 4.52% of the outstanding shares have been sold short.
| Short Interest | 6.71M |
| Short Previous Month | 7.29M |
| Short % of Shares Out | 4.52% |
| Short % of Float | 5.72% |
| Short Ratio (days to cover) | 6.84 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $418.63 million and earned $48.58 million in profits. Earnings per share was $0.32.
| Revenue | 418.63M |
| Gross Profit | 345.62M |
| Operating Income | 63.89M |
| Pretax Income | 66.26M |
| Net Income | 48.58M |
| EBITDA | 78.77M |
| EBIT | 63.89M |
| Earnings Per Share (EPS) | $0.32 |
Balance Sheet
The company has $166.12 million in cash and $22.53 million in debt, with a net cash position of $143.59 million or $0.97 per share.
| Cash & Cash Equivalents | 166.12M |
| Total Debt | 22.53M |
| Net Cash | 143.59M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 256.55M |
| Book Value Per Share | 1.73 |
| Working Capital | 213.21M |
Cash Flow
In the last 12 months, operating cash flow was $74.00 million and capital expenditures -$1.03 million, giving a free cash flow of $72.97 million.
| Operating Cash Flow | 74.00M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | 72.97M |
| FCF Per Share | $0.49 |
Margins
Gross margin is 82.56%, with operating and profit margins of 15.26% and 11.60%.
| Gross Margin | 82.56% |
| Operating Margin | 15.26% |
| Pretax Margin | 15.83% |
| Profit Margin | 11.60% |
| EBITDA Margin | 18.82% |
| EBIT Margin | 15.26% |
| FCF Margin | 17.43% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.45% |
| Shareholder Yield | -0.45% |
| Earnings Yield | 7.71% |
| FCF Yield | 11.58% |
Analyst Forecast
The average price target for MiMedx Group is $10.00, which is 135.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 135.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 4.76% |
| EPS Growth Forecast (5Y) | 7.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 9.85 and a Piotroski F-Score of 6.
| Altman Z-Score | 9.85 |
| Piotroski F-Score | 6 |